Navigation Links
Carrington and Universal Harvest Sign Supply Agreement
Date:2/25/2008

- One-year Agreement With Guaranteed Purchase Minimums

- Carrington Provides Product Development, Manufacturing and Global

Distribution

IRVING, Texas, Feb. 25 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) announced today it has signed a supply agreement with Universal Harvest Corporation of Nevada. Under the terms of this agreement, Carrington will provide Universal Harvest with product development, manufacturing and packaging services. The agreement provides guaranteed revenues, on a quarterly basis, for 2008.

The product covered under this agreement will contain a proprietary raw material from Carrington's Costa Rican subsidiary Sabila Industrial. Sabila Industrial will also be involved in manufacturing of the finished product for international users.

Doug Golwas, Carrington's vice president, corporate sales and marketing, stated, "Carrington is focused on aggressively marketing our ISO-certified, cGMP liquid filling capabilities. We have a long history of providing a quality and geographic advantage for our customers for these types of services. This agreement is evidence that the market finds strategic and economic value in this segment of our business."

Both parties have agreed to enter into discussions for a long-term extension prior to the expiration of the agreement.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) polymer technology designed to provide controlled release of peptide and protein-based drugs. A second technology GelVac(TM) is designed for dry powder nasal delivery of vaccines without the need for preservatives, adjuvants, cold storage and shipping under cold conditions. One influenza vaccine, (H5N1 antigen) with this technology, has been stable for more than three years at room temperature.

Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.


'/>"/>
SOURCE Carrington Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
2. Carrington Settles Lawsuit, Sets Sights On Future
3. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
4. Carrington Reports Third Quarter 2007 Results
5. Carrington Reports on ISO 9001:2000 Inspection
6. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
7. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
8. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
9. Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica
10. Carrington Completes $8 Million Financing
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... that it has joined the Human Vaccines Project, a public-private partnership to ... cancer. , The Human Vaccines Project brings together leading pharmaceutical and ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual ... is expecting to fill more than 100 tables for its annual event, which ...
Breaking Biology Technology:
(Date:1/13/2016)... , January 13, 2016 ... has published a new market report titled - Biometric Sensors ... and Forecast, 2015 - 2023. According to the report, the global ... and is anticipated to reach US$1,625.8 mn by 2023, ... 2023. In terms of volume, the biometric sensors market ...
(Date:1/11/2016)... Synaptics Incorporated (NASDAQ: SYNA ), the ... its ClearPad ® TouchView ™ 4300 touch ... categories in the 8 th Annual Mobile Excellence ... The Synaptics ® TDDI solution enables faster time-to-market, ... devices, brighter displays and borderless designs. ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 ... innovative sensor-based diagnostic products, today announced the closing of a ... existing investors.  Proceeds from the financing will be used to ... hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has ...
Breaking Biology News(10 mins):